
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of March 2021

Commission file number: 001- 38556

ENTERA BIO LTD.
(Translation of registrant's name into English)

**Kiryat Hadassah
Minrav Building – Fifth Floor
Jerusalem, Israel**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

CONTENTS

Results of the Extraordinary General Meeting of the Shareholders

On March 3, 2021, Entera Bio Ltd. (the “**Company**”) held an extraordinary general meeting of shareholders (the “**Meeting**”). At the Meeting, the Company’s shareholders voted on a proposal, which is described in more detail in the Company’s proxy statement for the Meeting attached as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K the Company filed with the Securities and Exchange Commission on January 11, 2021 (the “**Proxy Statement**”).

Based on the results and the majority requirements under the Israeli Companies Law 5759-1999 (the “**Companies Law**”) and the Company’s Articles of Association, the shareholders of the Company duly approved the following resolutions:

To ratify and approve the terms of compensation of Dr. Spiros Jamas, our Chief Executive Officer and director, for a period commencing as of January 4, 2021, and onward;

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Entera Bio Ltd.
(Registrant)

By: /s/ Dr. Spiros Jamas

Name: Spiros Jamas

Title: Chief Executive Officer

Date: March 3, 2021
